📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-08 17:16
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Akums Reports 56.1% PAT Growth in Q1 FY27; Revenue Up 14% to ₹1,167 Cr
Akums Drugs and Pharmaceuticals delivered a strong Q1 FY27 performance with consolidated revenue growing 13.9% YoY to ₹1,167 Cr. Net profit (PAT) surged 56.1% YoY to ₹101 Cr, supported by a 240 bps expansion in EBITDA margins to 15.0%. Growth was primarily driven by the core CDMO segment, which grew 18.6% YoY, while the company also finalized the ₹56 Cr acquisition of Oriflame India's manufacturing business to enter the color cosmetics market.
Confidence: HIGH
What changedAkums has demonstrated significant margin expansion and confirmed its entry into the specialized color cosmetics and wellness manufacturing space through the Oriflame acquisition.
Why it mattersThe results validate Akums' dominant 30.2% share in the Indian CDMO market and its ability to scale margins as capacity utilization improves. The diversification into cosmetics provides a new high-margin growth lever beyond traditional pharmaceuticals.
Revenue (Q1 FY27): ₹1,167 CrPAT Growth (YoY): 56.1%EBITDA Margin: 15.0%Oriflame Acquisition Value: ₹56 CrCDMO Revenue Growth: 18.6%Acquisition vs Market Cap: ~0.52%
📅 Short termThe stock is likely to react positively to the strong bottom-line growth and margin expansion, which exceeded the previous year's quarterly averages.
📈 Long termStructural growth remains intact through CDMO leadership, planned expansion into European markets by 2027, and inorganic growth supported by a strong net cash position.
⚠ Risk flags
- Muted performance in international branded formulations
- Volatility in API prices
- Operating costs associated with ramping up new injectable facilities
Key Highlights
Consolidated Revenue increased 13.9% YoY to ₹1,167 Cr, led by double-digit volume growth in CDMO.
EBITDA grew 35.4% YoY to ₹175 Cr, with margins improving from 12.6% to 15.0% due to operating leverage.
CDMO segment revenue reached ₹964 Cr, contributing 82.6% of total revenue with 50% capacity utilization.
Acquisition of Oriflame India's manufacturing business for ₹56 Cr adds two facilities in Noida and Roorkee.
API segment losses were curtailed as the business moves toward EBITDA-positive status with higher non-cepha product share.
👀 What to Watch
Monitor the commercialization timeline of the Jammu plant expected in FY27 and the margin trajectory of the newly acquired cosmetics business. Investors should also track the recovery of the international branded formulations segment, which saw a 1.5% YoY decline this quarter.
Akums Q1 FY27: PAT Surges 55% to ₹101 Cr; EBITDA Margins Expand to 15.0%
Akums Drugs and Pharmaceuticals reported a strong start to FY27 with consolidated revenue growing 13.9% YoY to ₹1,167 crore. The core CDMO segment remained the primary driver, contributing ₹964 crore (82.6% of total revenue) and growing 18.6% YoY. Operating profitability (EBITDA) increased significantly by 35.4% to ₹175 crore, with margins expanding 240 bps to 15.0%. Net profit (PAT) rose 55.4% YoY to ₹101 crore, reflecting improved operating leverage and a recovery in API prices.
Confidence: HIGH
What changedAkums has demonstrated a significant improvement in operating margins (reaching 15%) and bottom-line growth compared to the previous fiscal year, driven by volume growth in its CDMO business.
Why it mattersAs India's largest CDMO with a 30.2% market share, the company's ability to expand margins while growing revenue indicates strong pricing power and successful absorption of previous ramp-up costs in its injectable plants.
Q1 FY27 Revenue: ₹1,167 crYoY Revenue Growth: 13.9%EBITDA Margin: 15.0%PAT: ₹101 crCDMO Revenue: ₹964 crRevenue vs TTM Revenue: 26.7%
📅 Short termThe stock is likely to react positively to the strong margin expansion and PAT growth, which outperformed revenue growth significantly.
📈 Long termStructural growth is supported by the upcoming Jammu plant and planned expansion into European markets by 2027, utilizing a strong net cash position for potential inorganic growth.
⚠ Risk flags
- Operating deleverage risks from new plant ramp-ups
- Tightening environmental regulations affecting operating costs
- Seasonality in international branded revenue
Key Highlights
Consolidated revenue increased 13.9% YoY to ₹1,167 crore in Q1 FY27.
EBITDA grew 35.4% YoY to ₹175 crore, with margins improving from 12.6% to 15.0%.
PAT surged 55.4% YoY to ₹101 crore compared to ₹65 crore in the previous year's quarter.
CDMO segment revenue grew 18.6% YoY to ₹964 crore, with segment EBITDA up 36.8%.
Q1 FY27 revenue represents approximately 26.7% of the company's TTM revenue of ₹4,359 crore.
👀 What to Watch
Investors should monitor the commercialization timeline of the Jammu plant (expected 2026-27) and the margin trajectory as new injectable facilities continue to ramp up and seek regulatory approvals.
Akums Q1 Standalone Revenue up 18% YoY to ₹392.28 Cr; PAT Stagnant at ₹44.84 Cr
Akums Drugs and Pharmaceuticals reported a standalone revenue of ₹392.28 Cr for Q1 FY27, marking an 18% growth over the ₹332.44 Cr reported in Q1 FY26. Despite the top-line growth, standalone Profit After Tax (PAT) remained flat at ₹44.84 Cr compared to ₹44.87 Cr YoY, primarily due to a 31.7% surge in raw material costs. The company confirmed 100% utilization of its ₹642.18 Cr IPO proceeds towards debt repayment and growth. A significant tax demand of ₹60.09 Cr is currently under appeal, which represents approximately 23% of the company's TTM PAT.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial performance and announced the complete exhaustion of its IPO funds for the intended objects.
Why it mattersThe results demonstrate healthy demand in the CDMO segment but highlight immediate margin pressure from input costs and a potential financial risk from a ₹60 Cr tax litigation.
Standalone Revenue (Q1 FY27): ₹392.28 CrStandalone PAT (Q1 FY27): ₹44.84 CrTax Demand under appeal: ₹60.09 CrIPO Proceeds Utilized: ₹642.18 CrTax Demand vs TTM PAT: ~23.4%
📅 Short termThe stock may see neutral to slightly cautious movement as the market weighs strong revenue growth against stagnant profits and the tax demand disclosure.
📈 Long termLong-term growth is tied to the commercialization of the Jammu plant and expansion into European markets starting 2027.
⚠ Risk flags
- Rising raw material costs impacting margins
- Unresolved tax demand of ₹60.09 Cr
- Operating deleverage from new plant ramp-ups
Key Highlights
Standalone Revenue from operations increased 18% YoY to ₹392.28 Cr.
Cost of materials consumed rose significantly to ₹253.56 Cr from ₹192.55 Cr in the previous year's quarter.
Standalone Profit After Tax (PAT) remained nearly flat at ₹44.84 Cr.
Total IPO proceeds of ₹642.18 Cr have been fully utilized as of June 30, 2026.
Income tax authorities raised a demand of ₹60.09 Cr for the block period April 2018 to March 2025, currently under appeal.
👀 What to Watch
Monitor the margin trajectory in upcoming quarters to see if the company can pass on rising material costs, and track the progress of the Jammu plant launch scheduled for 2026-27.
Akums Q1 FY27 Standalone Revenue at ₹392.28 Cr; ₹60.09 Cr Tax Demand Disclosed
Akums Drugs and Pharmaceuticals reported standalone revenue of ₹392.28 Cr for Q1 FY27, an 18% increase from ₹332.44 Cr in Q1 FY26. Standalone net profit remained flat at ₹44.84 Cr compared to ₹44.87 Cr in the year-ago period, reflecting margin pressure. A significant tax demand of ₹60.09 Cr was disclosed for the period 2018-2025, which the company is currently appealing. The company also confirmed full utilization of its ₹680 Cr IPO proceeds, primarily for debt repayment and working capital.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27 and provided a final update on the utilization of its ₹680 Cr IPO proceeds.
Why it mattersWhile revenue is growing, the flat profit growth and the ₹60.09 Cr tax demand (representing ~23% of TTM PAT) are key areas of concern for short-term valuation.
Standalone Revenue (Q1 FY27): ₹392.28 CrStandalone PAT (Q1 FY27): ₹44.84 CrTax Demand: ₹60.09 CrTax Demand vs TTM PAT: ~23.4%IPO Proceeds Utilized: ₹680 Cr
📅 Short termThe stock may face pressure due to flat profit growth and the disclosure of the ₹60.09 Cr tax liability, despite healthy revenue growth.
📈 Long termLong-term growth depends on the successful commercialization of the Jammu plant in FY27 and the utilization of the ₹1,600 Cr cash position for strategic acquisitions.
⚠ Risk flags
- Tax demand of ₹60.09 Cr under appeal
- Stagnant standalone profit growth despite revenue increase
- Operating deleverage risks from new plant ramp-ups
Key Highlights
Standalone revenue grew 18% YoY to ₹392.28 Cr in Q1 FY27 from ₹332.44 Cr in Q1 FY26.
Standalone net profit for the quarter stood at ₹44.84 Cr, showing negligible growth over the previous year's ₹44.87 Cr.
Disclosed a tax demand of ₹60.09 Cr following a search and seizure operation for the block period April 2018 to March 2025.
Fully utilized ₹680 Cr raised through the IPO, with ₹426.3 Cr directed toward debt repayment for the company and its subsidiaries.
Allocated ₹30.18 Cr from IPO proceeds specifically for pursuing inorganic growth initiatives.
👀 What to Watch
Investors should monitor the outcome of the ₹60.09 Cr tax appeal and the operational ramp-up of the Jammu plant, which is expected to drive future growth.
₹56 Cr Acquisition: Akums to Buy Oriflame India's Manufacturing Business
Akums Drugs and Pharmaceuticals, through its subsidiary Pure and Cure Healthcare, has approved the acquisition of Oriflame India's manufacturing business for ₹56 crore in cash. The deal includes two manufacturing plants in Roorkee and Noida, along with a leased warehouse, marking Akums' entry into the color cosmetics segment. While the acquisition cost is relatively small at ~1.3% of TTM revenue, it represents a strategic diversification into skincare and wellness. The transaction is expected to be completed by August 31, 2026, and notably excludes Oriflame's trademarks and marketing rights.
Confidence: HIGH
What changedAkums is expanding its CDMO capabilities from pure pharmaceuticals and wellness into the color cosmetics manufacturing space through an asset purchase from Oriflame India.
Why it mattersThis move allows Akums to diversify its revenue streams into high-growth consumer categories using its existing cash reserves, without the complexity of acquiring a full corporate entity or marketing liabilities.
Acquisition Cost: ₹56 CroreCost vs TTM Revenue: ~1.28%Cost vs Net Worth: ~2.31%Completion Date: August 31, 2026Manufacturing Plants Acquired: 2
📅 Short termThe market is likely to view this as a positive use of cash for inorganic growth, though the immediate financial impact on the ₹4,359 Cr revenue base will be modest.
📈 Long termThis establishes a foothold in the cosmetics CDMO market, potentially allowing Akums to leverage its existing client relationships with large pharma-FMCG players who are also expanding into beauty.
⚠ Risk flags
- Execution risk in entering the specialized color cosmetics category
- Exclusion of trademarks means Akums must secure its own B2B manufacturing clients for these plants
Key Highlights
Total cash consideration of ₹56 Crore for the manufacturing business assets
Acquisition includes 2 manufacturing plants located in Roorkee (Uttarakhand) and Noida (Uttar Pradesh)
Expected completion date for the entire transaction is August 31, 2026
Marks Akums' strategic entry into the color cosmetics and wellness manufacturing market
Acquisition cost represents approximately 3.5% of the company's reported ₹1,600 Cr net cash position
👀 What to Watch
Watch for the successful integration of these plants by the August 31 deadline and any subsequent announcements regarding new B2B contracts in the cosmetics segment to gauge utilization.
Akums Drugs Announces ₹3 Dividend and AGM for July 10, 2026
Akums Drugs and Pharmaceuticals has scheduled its 22nd Annual General Meeting for July 10, 2026. The company has recommended a total dividend of ₹3 per share, consisting of a ₹1 final dividend and a ₹2 special dividend for FY 2025-26. A significant agenda item includes the proposed revision of remuneration for Managing Directors Sanjeev Jain and Sandeep Jain, capped at ₹12 Crores per annum each. The record date for the dividend payout is fixed as July 03, 2026.
Key Highlights
Total dividend of ₹3 per share (150% of face value) recommended for FY 2025-26.
Record date for dividend eligibility is set for July 03, 2026.
Proposed hike in remuneration for Managing Directors to a maximum of ₹12 Crores per annum.
22nd AGM to be conducted via Video Conferencing on July 10, 2026.
Ratification of Cost Auditor remuneration at ₹3,00,000 for the financial year 2026-27.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of July 03, 2026. Shareholders should also review the rationale for the significant management remuneration hike during the AGM.
Akums Drugs to Hold 22nd AGM on July 10; Final and Special Dividend Proposed
Akums Drugs and Pharmaceuticals Limited has scheduled its 22nd Annual General Meeting (AGM) for July 10, 2026, via video conferencing. The company is moving forward with the distribution of both a Final and a Special Dividend for the financial year 2025-26, as recommended by the Board on May 14, 2026. The Integrated Annual Report for FY26 will be dispatched electronically to registered shareholders. This announcement signals a dual-dividend payout, which is typically a strong indicator of cash flow health.
Key Highlights
22nd Annual General Meeting (AGM) scheduled for July 10, 2026, at 11:00 AM IST.
Proposal for both a Final Dividend and a Special Dividend for the financial year 2025-26.
Board of Directors recommended the dividend payouts in a meeting held on May 14, 2026.
Integrated Annual Report and AGM notice to be distributed electronically to registered members.
Remote e-voting facility to be provided through NSDL for all eligible shareholders.
👀 What to Watch
Investors should monitor for the specific dividend amounts and the record date in the upcoming detailed notice to ensure eligibility. Shareholders are advised to update their email addresses with their Depository Participants to receive the Integrated Annual Report.
Akums Subsidiaries Receive Income Tax Demands Totaling ₹22.26 Crore
Four wholly-owned subsidiaries of Akums Drugs and Pharmaceuticals have received assessment orders from the Income Tax Department for the block period April 2018 to March 2025. The total tax demand across these entities amounts to approximately ₹22.26 crore, primarily due to the disallowance of various expenditures under Section 37(1) of the Income Tax Act. Maxcure Nutravedics Limited faces the largest individual demand of ₹15.24 crore. The company has stated that it intends to appeal these orders, believing the demands are not legally sustainable and will not have a material financial impact.
Key Highlights
Total tax demand of ₹22.26 crore issued against four wholly-owned subsidiaries.
Maxcure Nutravedics Limited received the highest demand of ₹15.24 crore.
Demands relate to a block period spanning nearly seven years from April 1, 2018, to March 12, 2025.
Disallowances were primarily made under Section 37(1) regarding business expenditures.
Management plans to appeal the orders, asserting that the demands are defendable on facts.
👀 What to Watch
Investors should monitor the outcome of the appeals process as a final adverse ruling would impact the company's cash reserves. However, given the management's intent to contest and the scale of the demand relative to the company's size, no immediate drastic action is required.
Akums Drugs FY26 Revenue Up 5.8% to ₹4,359 Cr; Board Declares ₹3 Total Dividend
Akums Drugs and Pharmaceuticals reported a steady performance for FY26 with revenue growing 5.8% YoY to ₹4,359 crores and adjusted EBITDA rising 13.3% to ₹522 crores. While reported PAT fell to ₹256 crores due to a one-time tax benefit in the previous year, Profit Before Tax (PBT) grew by 11.9% to ₹382 crores. The company's core CDMO segment remains strong, and the Trade Generics business successfully turned EBITDA positive in Q4. Management is focusing on high-margin regulated markets following EU GMP accreditation for its second plant.
Key Highlights
Adjusted EBITDA for FY26 rose 13.3% to ₹522 crores with margins expanding to 12% from 11.2%.
CDMO segment revenue grew 8.6% YoY to ₹3,485 crores, driven by double-digit volume expansion.
Trade Generics business turned EBITDA positive in Q4 FY26 at ₹1.4 crores vs a loss of ₹10 crores YoY.
Board recommended a final dividend of ₹1 and a special dividend of ₹2 per equity share for FY26.
Operating cash flow significantly improved to ₹1,181 crores compared to ₹465 crores in FY25.
👀 What to Watch
Investors should focus on the company's transition toward regulated markets and the scaling of the European dossier pipeline. The turnaround in the Trade Generics segment and strong cash flow generation provide a solid foundation for future capacity expansions.
Akums Drugs & Subsidiary Receive Income Tax Demand Orders Totaling ₹133.75 Crore
Akums Drugs and Pharmaceuticals and its subsidiary, Akumentis Healthcare, have received assessment orders from the Income Tax Department for the block period FY 2018-19 to FY 2024-25. The total tax demand amounts to ₹133.75 crore, comprising ₹60.09 crore for the parent company and ₹73.66 crore for the subsidiary. The demands are based on the disallowance of various expenditures under Section 37(1) of the Income Tax Act. The company maintains that these demands are not legally sustainable and intends to file appeals against the orders.
Key Highlights
Total tax demand of ₹133.75 crore raised by the Income Tax Department.
Parent company Akums Drugs faces a demand of ₹60.09 crore.
Subsidiary Akumentis Healthcare faces a demand of ₹73.66 crore.
Assessment covers a block period from April 1, 2018, to March 12, 2025.
Disallowances relate to expenditures claimed under Section 37(1) of the Income Tax Act.
👀 What to Watch
Investors should monitor the litigation progress as tax disputes can be lengthy and may require partial deposits of the demand amount. While the company plans to appeal, a liability of this size represents a potential risk to future cash flows.
Akums Resumes 100% Operations at Haridwar; INR 20 Cr Supply Delay to be Recovered
Akums Drugs and Pharmaceuticals has successfully restored 100% manufacturing capacity at its Haridwar sites as of May 18, 2026. The facilities faced a partial disruption lasting four days, which resulted in a temporary supply delay valued at approximately INR 20 crore. The company reported no physical damage to its property and will not be filing any insurance claims. Management expects to fully recover the production loss in the coming weeks, suggesting minimal long-term impact on financials.
Key Highlights
Manufacturing operations at Haridwar sites resumed at 100% capacity on May 18, 2026.
The partial disruption lasted for four days, leading to a supply delay of approx. INR 20 crore.
No physical damage was caused to company property during the disruption period.
Management intends to make up for the production loss in the upcoming weeks.
No insurance claims will be filed as there was no property damage.
👀 What to Watch
Investors should note the quick operational recovery, which indicates strong resilience; monitor the next quarterly report to confirm the recovery of the INR 20 crore supply delay.
Akums Resumes Over 70% Operations at Haridwar Plants Following Labor Unrest
Akums Drugs has resumed over 70% of its manufacturing operations at Haridwar sites as of May 16, 2026, following a brief disruption. The disruption was part of an industry-wide labor unrest in Uttarakhand triggered by a state review of minimum wages, affecting multiple sectors. The company confirmed no property damage occurred, and production losses are covered under their industrial insurance policy. Management expects productivity to improve progressively as local authorities work to restore full normalcy across the region.
Key Highlights
Manufacturing operations resumed at over 70% capacity starting May 16, 2026
Disruption was industry-wide across Uttarakhand due to state-level minimum wage reviews
No physical damage to property; production losses are covered by insurance
Operations at other manufacturing units outside Haridwar remained stable and unaffected
👀 What to Watch
Investors should monitor the timeline for 100% capacity restoration and any potential impact on labor costs due to the minimum wage review. The insurance coverage mitigates short-term production losses, suggesting the impact may be temporary.
Akums Drugs Reports FY26 Revenue of ₹4,359 Cr, Adjusted PAT Up 27.3%
Akums Drugs and Pharmaceuticals Limited reported a steady FY26 with consolidated revenue growing 5.8% YoY to ₹4,359 crore, primarily driven by its core CDMO segment. Adjusted EBITDA rose 13.3% to ₹522 crore, while Adjusted PAT saw a significant 27.3% increase to ₹276 crore. The company successfully utilized IPO proceeds to repay ₹387 crore in debt and turned its Trade Generics business EBITDA positive in Q4. Strategic growth is underpinned by a €200 million European CDMO contract and a new $25 million annual supply commitment from a Zambia JV starting FY27.
Key Highlights
FY26 Revenue grew 5.8% YoY to ₹4,359 crore, with the CDMO segment contributing 80% of total revenue.
Adjusted PAT for FY26 increased 27.3% YoY to ₹276 crore; Q4 FY26 Adjusted PAT surged 134.9% YoY to ₹83 crore.
Secured a €200 million multi-year European CDMO contract with supplies starting in FY28.
Zambia JV (51% stake) secured a $25 million per annum supply commitment for FY27 and FY28.
Overall capacity utilization improved to 44% for FY26, supported by double-digit volume growth in CDMO.
👀 What to Watch
Investors should focus on the company's transition toward higher-margin international markets and the execution of the €200 million European contract. While the API segment still faces losses, the debt reduction and positive momentum in Trade Generics strengthen the balance sheet for future expansion.
Akums Q4 FY26 PAT Jumps 135% YoY to ₹83 Cr; Total Dividend of ₹3 Declared
Akums Drugs and Pharmaceuticals reported a robust Q4 FY26 with Adjusted PAT surging 135% YoY to ₹83 crore, driven by strong performance in its core CDMO segment. Revenue for the quarter grew 9.7% to ₹1,158 crore, while Adjusted EBITDA margins expanded significantly to 13.1% from 8.9% in the previous year. The company also announced a total dividend of ₹3 per share, including a ₹2 special dividend. While the API business remains under pressure with operating losses, the trade generics segment successfully turned EBITDA positive during the quarter.
Key Highlights
Q4 Adjusted PAT grew 135% YoY to ₹83 crore with Adjusted EBITDA rising 61.6% to ₹152 crore.
Core CDMO segment revenue reached ₹952 crore in Q4, with segment EBITDA margins improving to 14.4%.
Board recommended a final dividend of ₹1 and a special dividend of ₹2 per share (Total 150% of face value).
Trade generics segment turned EBITDA positive at ₹1.4 crore in Q4, compared to losses in previous periods.
API business reported an operating loss of ₹12 crore in Q4 due to ongoing global pricing pressures.
👀 What to Watch
Investors should take note of the significant margin expansion in the CDMO business and the turnaround in trade generics. The stock remains a watch for further recovery in the API segment and the scaling of international operations following recent UK MHRA and EU GMP approvals.
Akums Drugs Reports Operational Disruption at Haridwar Sites Due to Labor Unrest
Akums Drugs and Pharmaceuticals Limited has announced a temporary disruption of operations at several of its manufacturing sites in Haridwar as of May 14, 2026. The disruption is a result of labor unrest occurring within the SIDCUL industrial area, affecting multiple units. Management is currently in discussions with local authorities and worker representatives to reach an amicable resolution. While the company is working to normalize operations, the full extent of the production and financial impact is still being assessed.
Key Highlights
Manufacturing operations at Haridwar sites disrupted on May 14, 2026, due to regional labor unrest.
The affected facilities are located in the SIDCUL industrial area, a key manufacturing hub for the company.
Management and local authorities are actively engaged in negotiations to resolve the issue quickly.
A formal assessment of the impact on production and financial performance is currently pending.
Company has committed to providing further updates as the situation evolves and operations resume.
👀 What to Watch
Investors should monitor the duration of the shutdown closely, as a prolonged disruption could impact near-term revenue and supply chain commitments. Wait for the company's assessment of the financial impact before making significant portfolio adjustments.
Akums Drugs Declares Total Dividend of ₹3 Per Share; Sets July 3, 2026 as Record Date
Akums Drugs and Pharmaceuticals has recommended a total dividend of ₹3.00 per equity share for FY 2025-26, comprising a ₹1.00 final dividend and a ₹2.00 special dividend. The company has fixed July 03, 2026, as the record date to determine eligibility for these payments, subject to shareholder approval at the upcoming AGM on July 10, 2026. Alongside the dividend, the board approved the audited financial results for the year ended March 31, 2026, and announced the appointment of Mr. V Jagannathan as the new President of HR. Investors should also note the ongoing Income Tax search and seizure proceedings, for which the company recently received a show cause notice.
Key Highlights
Recommended a total dividend of ₹3.00 per share (150% of face value ₹2), including a ₹2.00 special dividend.
Fixed July 03, 2026, as the record date for dividend eligibility with payment within 30 days of AGM approval.
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Appointed Mr. V Jagannathan as President – HR, effective May 14, 2026, following the cessation of Mr. Arvind Srivastava.
Disclosed receipt of a show cause notice under section 158BC of the Tax Act regarding a 2025 search and seizure operation.
👀 What to Watch
Investors interested in the dividend payout should ensure they hold the stock prior to the July 3 record date. While the special dividend is a positive signal, shareholders should monitor further disclosures regarding the Income Tax show cause notice for potential financial impact.
Akums Drugs Declares ₹3 Total Dividend and Announces New HR Leadership
Akums Drugs and Pharmaceuticals has recommended a combined dividend of ₹3.00 per equity share for FY26, consisting of a ₹1.00 final dividend and a ₹2.00 special dividend. The company announced a transition in senior management with Mr. V Jagannathan appointed as President – HR, replacing Mr. Arvind Srivastava. While the board approved the annual financial results, the statutory auditors highlighted an ongoing Income Tax search and seizure investigation initiated in 2025. The company has recently received a show cause notice under section 158BC, the financial impact of which is currently unascertainable.
Key Highlights
Recommended a total dividend of ₹3.00 per share (150% of face value), including a ₹2.00 special dividend.
Fixed July 3, 2026, as the record date for dividend eligibility.
Appointed Mr. V Jagannathan as President – HR effective May 14, 2026.
Statutory auditors issued an 'Emphasis of Matter' regarding ongoing Income Tax search and seizure proceedings.
Appointed Mahajan & Aibara LLP as Internal Auditors for the 2026-27 financial year.
👀 What to Watch
Investors should enjoy the high dividend yield but remain cautious regarding the legal overhang from the Income Tax department's show cause notice. Monitor future disclosures for any quantified tax liabilities that may arise from the ongoing proceedings.
Akums Drugs Declares ₹3 Total Dividend and Announces Senior Management Changes
Akums Drugs and Pharmaceuticals has recommended a total dividend of ₹3 per share for FY 2025-26, comprising a ₹1 final dividend and a ₹2 special dividend. The company announced a transition in its HR leadership, appointing Mr. V Jagannathan as President – HR following the cessation of Mr. Arvind Srivastava. Mahajan & Aibara LLP has been appointed as the new Internal Auditor for the upcoming financial year. Investors should be aware of an ongoing Income Tax search and seizure matter, for which the company has recently received a show-cause notice.
Key Highlights
Recommended a total dividend of ₹3.00 per share (150% of face value ₹2), including a ₹2.00 special dividend.
Fixed July 03, 2026, as the record date for dividend eligibility with payment within 30 days of AGM approval.
Appointed Mr. V Jagannathan as President – HR and Senior Management Personnel effective May 14, 2026.
Appointed Mahajan & Aibara LLP as Internal Auditors and re-appointed Balwinder & Associates as Cost Auditors for FY 2026-27.
Disclosed receipt of a show-cause notice under Section 158BC regarding the Income Tax search conducted in January 2025.
👀 What to Watch
Investors should benefit from the high dividend payout but must monitor the potential financial impact of the ongoing Income Tax search and seizure proceedings.
Akums Drugs Declares ₹3 Dividend, Appoints New HR Head and Reports FY26 Results
Akums Drugs and Pharmaceuticals has recommended a total dividend of ₹3.00 per share, comprising a ₹1.00 final dividend and a ₹2.00 special dividend for FY 2025-26. The company announced a transition in its senior management with Mr. V Jagannathan taking over as President – HR. While the board approved the annual financial results, the statutory auditors highlighted an ongoing Income Tax search and seizure investigation, noting that a show-cause notice was recently received. The record date for the dividend has been fixed as July 03, 2026, subject to shareholder approval.
Key Highlights
Recommended a total dividend of ₹3.00 per share (₹1.00 final and ₹2.00 special) on a face value of ₹2.00.
Set July 03, 2026, as the record date for dividend eligibility with payment within 30 days of AGM approval.
Appointed Mr. V Jagannathan as President – HR following the cessation of Mr. Arvind Srivastava.
Statutory auditors issued an 'Emphasis of Matter' regarding an ongoing Income Tax search and seizure case initiated in January 2025.
Appointed Mahajan & Aibara LLP as Internal Auditors for the financial year 2026-27.
👀 What to Watch
Investors should balance the positive dividend announcement against the regulatory risk posed by the ongoing Income Tax investigation. Monitor the company's response to the show-cause notice as the potential financial impact remains unascertainable.
Akums Drugs Reports FY26 Results, Declares ₹3 Total Dividend per Share
Akums Drugs and Pharmaceuticals has approved its annual financial results for FY26 and recommended a total dividend of ₹3.00 per share, which includes a ₹2.00 special dividend. The company has fixed July 03, 2026, as the record date for the dividend payout. A significant point of concern is the auditor's 'Emphasis of Matter' regarding an ongoing Income Tax search and seizure operation from 2025, for which the company recently received a show-cause notice. Additionally, the company announced the appointment of Mr. V Jagannathan as the new President of HR.
Key Highlights
Recommended a total dividend of ₹3.00 per share (₹1.00 final and ₹2.00 special) on a face value of ₹2.00.
Fixed July 03, 2026, as the record date for determining shareholder eligibility for dividends.
Statutory auditors highlighted a pending Income Tax search and seizure case with a recently received show-cause notice.
Appointed Mr. V Jagannathan as President – HR, effective May 14, 2026, replacing Mr. Arvind Srivastava.
The 22nd Annual General Meeting (AGM) is scheduled for July 10, 2026.
👀 What to Watch
While the special dividend is a positive for shareholders, the unresolved Income Tax investigation represents a regulatory risk. Investors should monitor further disclosures regarding the tax show-cause notice for potential financial impacts.
